Bob Duggan, Summit Therapeutics CEO
September 8, 2024 11:39 AM EDTUpdated September 9, 06:54 AM
R&D
China

Sum­mit's Phase 3 da­ta back up biotech's boasts of beat­ing Keytru­da in lung can­cer

Andrew Dunn

Senior Biopharma Correspondent

A few months af­ter Sum­mit Ther­a­peu­tics shocked the on­col­o­gy world with an ear­ly claim that its lung can­cer drug ivonescimab had beat­en …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times